Effect of age on lipid profiles in pediatric heart transplant recipients

Pediatric Transplantation

Volumn 9, Issue 4, 2005, Pages 523-530

  Armstrong, Aimee K ^a   Goldberg, Caren S ^a   Crowley, Dennis C ^a   Wei, Wei ^b   Gajarski, Robert J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Heart transplantation; Hyperlipidemia; Immunosuppression; Pediatric

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISONE; TACROLIMUS;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PEDIATRIC SURGERY; RETROSPECTIVE STUDY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADRENAL CORTEX HORMONES; AGE FACTORS; ANTILIPEMIC AGENTS; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; HEART TRANSPLANTATION; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; LINEAR MODELS; MALE; PREDNISONE; RETROSPECTIVE STUDIES;

EID: 23844456577     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2005.00330.x     Document Type: Article

References (25)

1. BECKER DM, CHAMBERLAIN B, SWANK R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988: 85: 632-638.
2. BALLANTYNE CM, PODET EJ, PATSCH WP, et al. Effects of cyclosporin therapy on plasma lipoprotein levels. JAMA 1989: 262: 53-56.
3. BAAN CC, VAN RIEMSDIJK-VAN OVERBEEKE IC, BALK AHMM, et al. Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-β1 type I receptor expression. Clin Transplant 2001: 15: 276-283.
4. BALLANTYNE CM, MASRI BE, MORRISETT JD, TORRE-AMIONE G. Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Curr Opin Cardiol 1997: 12: 153-160.
5. AKHLAGHI F, JACKSON CH, PARAMESHWAR J, SHARPLES LD, TRULL AK. Risk factors for the development and progression of dyslipidemia after heart transplantation. Transplantation 2002: 73: 1258-1264.
6. ALONSO DR, STAREK PK, MINICK CR. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol 1977: 87: 415-435.
7. KAPADIA SR, NISSEN SE, ZIADA KM, et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: A serial intravascular ultrasound study. J Am Coll Cardiol 2001: 38: 206-213.
8. BEHRENDT D, GANZ P, FANG JC. Cardiac allograft vasculopathy. Curr Opin Cardiol 2000: 15: 422-429.
9. BOUCEK MM, EDWARDS LB, KECK BM, et al. The registry of the International Society for Heart and Lung Transplantation: Fifth official pediatric report-2001 to 2002. J Heart Lung Transplant 2002: 21: 827-840.
10. SEIPELT IM, CRAWFORD SE, RODGERS S, et al. Hypercholesterolemia is common after pediatric heart transplantation: Initial experience with pravastatin. J Heart Lung Transplant 2004: 23: 317-322.
11. CHIN C, ROSENTHAL D, BERNSTEIN D. Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. Pediatr Transplant 2000: 4: 193-199.
12. DIFILIPPO S, SASSOLAS A, SASSOLAS F, SEMIOND B, BOZIO A. Changes in serum cholesterol, lipoproteins and triglycerides after cardiac transplantation in children. Arch Mal Coeur Vaiss 2001: 94: 464-469.
13. National Center for Health Statistics. 2000 CDC Growth charts: United States. Available from: URL: http:// www.cdc.gov/growthcharts.
14. Expert Panel on Blood Cholesterol Levels in Children and Adolescents. National cholesterol education program: Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992: S89: 525-584.
15. LAW YM, YIM R, AGATISA PK, et al. Lipid profiles in pediatric thoracic recipients are determined by the immunosuppressive regimens [abstract]. J Heart Lung Transplant 2002: 21: 172.
16. VALANTINE HA. Role of lipids in allograft vascular disease: A multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant 1995: 14: S234-S237.
17. CHIN C, GAMBERG P, MILLER J, LUIKART H, BERNSTEIN D. Efficacy and safety of atorvastatin after pediatric heart transplantation. J Heart Lung Transplant 2002: 21: 1213-1217.
18. WEIS M. Cardiac allograft vasculopathy: Prevention and treatment options. Transplant Proc 2002: 34: 1847-1849.
19. FENSTER BE, TSAO PS, ROCKSON SG. Endothelial dysfunction: Clinical strategies for treating oxidant stress. Am Heart J 2003: 146: 218-226.
20. JARVISALO MJ, TOIKKA JO, VASANKARI T, et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999: 147: 237-242.
21. MCCRINDLE BW, OSE L, MARAIS AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: A multicenter, randomized, placebo-controlled trial. J Pediatr 2003: 142: 74-80.
22. STEIN EA, ILLINGWORTH DR, KWITEROVICH PO, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: A randomized controlled trial. JAMA 1999: 281: 137-144.
23. DEJONGH S, OSE L, SZAMOSI T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002: 106: 2231-2237.
24. MCCRINDLE BW, HELDEN E, CULLEN-DEAN G, CONNER WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res 2002: 51: 715-721.
25. HANAKA S, ABE T, ITAKURA H, MATSUMOTO A. Gene expression related to cholesterol metabolism in mouse brain during development. Brain Dev 2000: 22: 321-326.